openPR Logo
Press release

Michel Mikhail invites Biosimilar experts to attend SMi’s 10th Annual Biosimilars Conference

05-14-2019 12:14 PM CET | Health & Medicine

Press release from: SMi Group

biosimilars, biobetters, interchangeability, medicine, biosimilars development, law, FDA

biosimilars, biobetters, interchangeability, medicine, biosimilars development, law, FDA

This year's event will address regulatory issues, alongside case reports of developing, forecasting and launching the next wave of biosimilars to ensure optimal uptake and successful commercialisation of these high-quality medicinal products.

Michel states:

"I am delighted to cordially invite you to our 10th Biosimilars Conference taking place on the 25th and 26th September 2019 at the Copthorne Tara Hotel in London, UK."

"After over a decade of successful experience with Biosimilars in Europe, the biosimilars industry is finally reaching a stage where key stakeholders better understand and accept biosimilars. This is reflected in the requirements for development, regulatory approval & post-marketing surveillance and an increased uptake of biosimilars across the globe.

We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or will the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?"

About Michel Mikhail:

Dr. Michel Mikhail has more than 30 years Pharmaceutical Industry experience and track record of achievement in R&D and International Regulatory Affairs in large multinational Research-based Pharmaceutical Companies, Biotech Companies as well as in the Generics industry. He is a Chartered Expert in Pharmacology-Toxicology, a chartered Clinical Expert as well as a chartered Analytical Expert. Dr. Mikhail is a Global Expert in Biosimilars and International Regulatory Affairs Expert. He served as member of the Expert committee of the Government Federal Institute of Risk Assessment (BfR) Germany and served as member of the Expert Committee for Toxicology of the United States Pharmacopoeia (USP).

The Biosimilars Conference two pre-conference, half-day workshops will commence on 24th September:

· Workshop A: "Interchangeability in the USA: The US-FDA Regulatory Guideline" led by Michel Mikhail, International Expert Regulatory Affairs, Global Expert of Biosimilars.

· Workshop B: "Advancing Biosimilars Development and Uptake in MENA and GCC Regions".

To download the 2-day conference agenda, half-day workshops and the expert speaker line-up, please visit the website at www.biosimilars-europe.com/pr2

Hear the experiences of prominent speakers and key opinion leaders and evaluate market access opportunities and commercialisation strategies with industry-thought experts at Biosimilars Conference 2019.

For those interested in attending, if you book your place by Friday 31st May you will save £300. Register online at www.biosimilars-europe.com/pr2

For sponsorship enquires, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk

SMi's 10th Annual Biosimilars Conference
Conference: 25-26 September 2019
Workshops: 24 September 2019
Copthorne Tara Hotel, London, UK
http://www.biosimilars-europe.com/pr2
#SMiBiosimilars

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

45 Curlew Street
Ground Floor

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Michel Mikhail invites Biosimilar experts to attend SMi’s 10th Annual Biosimilars Conference here

News-ID: 1738360 • Views: 362

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Biosimilars

Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on